Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Please find enclosed intimation pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby furnish the details of loss of share certificates/request for issue of duplicate share certificate reported by shareholders of the Company, received from our Registrar and Transfer Agent, Link lntime India Private Limited on March 5, 2020.
05-03-2020
Bigul

Pharma stocks gain for second straight day; Sun Pharma surges 12% in 2 days

 According to CARE Ratings, pharma exports from India are estimated to rise by about 11 to 12 per cent on a year on year.
04-03-2020
Bigul

Shanghvi Finance raises stake in Sun Pharma

 Shares of Sun Pharma ended up 6.6 per cent at Rs 393.35 on Tuesday.
04-03-2020

Sun Pharma share price up 3% after Morgan Stanley remains overweight

 The stock was trading with volumes of 654,539 shares, compared to its five-day average of 422,811 shares, an increase of 54.81 percent.
03-03-2020
Bigul

Sun Pharma's hypertension drug in shortage in US due to shortfall in active ingredients

 Drugmaker Sun Pharmaceutical Industries Ltd reported a shortage of its generic version of hypertension drug pindolol in the US due to a lack of pharm
02-03-2020
Bigul

Coronavirus outbreak: Don't panic over supplies, says pharma industry

 Sun Pharma's Dilip Shanghvi said the industry and government were working closely to reduce dependence on one country
29-02-2020
Bigul

Sun Pharmaceutical Industries Ltd - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 28, 2020 for Shanghvi Finance Pvt Ltd
28-02-2020
Bigul

Sun Pharmaceutical Industries Ltd - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 28, 2020 for Aditya Medisales Ltd
28-02-2020
Bigul

Sun Pharma launches diabetes drug in the US market

 Sun Pharmaceutical Industries on Wednesday said its wholly-owned subsidiary had launched Riomet ER, used to treat type 2 diabetes mellitus, in the US
26-02-2020
Bigul

SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Please find enclosed herewith our Press Release relating to Riomet ER oral suspension launch in the US, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,
26-02-2020
Next Page
Close

Let's Open Free Demat Account